Abstract
Introduction: The aim of this study was to investigate the association of pre-treatment-modified Glasgow Prognostic Score (mGPS) with survival-related outcomes in patients with bladder cancer (BC) and prostate cancer (PC). Methods: A systematic search was performed in PubMed, EMBASE, Web of Science, and Scopus databases for cohort studies in adult participants (≥18 years). The exposure was pre-treatment mGPS, and the outcomes of interest were overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Eligible studies compared low mGPS (considered as a score of 0) with a score of ≥1. A random-effects model was used for the analysis. Pooled effect sizes were reported as hazard ratio (HR) with 95% confidence intervals (CIs). Subgroup analysis was performed based on the tumour stage (≤T2 and >T2), sample size (≥200 and <200), treatment (surgical and non-surgical), and the Newcastle-Ottawa Scale (NOS) score (≥8 and ≤7). Results: Of 20 studies included in the analysis, 19 studies were retrospective cohort studies. Fourteen studies reported data of patients with BC, and the remaining 6 studies focused on PC patients. Compared to mGPS of 0, higher scores were associated with reduced OS (HR: 2.65; 95% CI: 1.99, 3.52), CSS (HR: 1.64; 95% CI: 1.19, 2.26), and RFS (HR: 1.77; 95% CI: 1.50, 2.08). There was no evidence of publication bias (Egger’s p > 0.05). These associations remained valid in subgroup analysis. Conclusion: Higher mGPS values were found to be associated with significantly reduced survival outcomes. These findings underscore the prognostic significance of mGPS, thereby highlighting its potential clinical utility in risk stratification and treatment decision-making.
Journal Section:
Systematic Review
References
1.
Sung
H
, Ferlay
J
, Siegel
RL
, Laversanne
M
, Soerjomataram
I
, Jemal
A
, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
. CA Cancer J Clin
. 2021
;71
(3
):209
–49
. 2.
Kluth
LA
, Black
PC
, Bochner
BH
, Catto
J
, Lerner
SP
, Stenzl
A
, et al. Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature
. Eur Urol
. 2015
;68
(2
):238
–53
. 3.
Fujii
Y
. Prediction models for progression of non-muscle-invasive bladder cancer: a review
. Int J Urol
. 2018
;25
(3
):212
–8
. 4.
Vickers
A
. Prediction models in urology: are they any good, and how would we know anyway
. Eur Urol
. 2010
;57
(4
):571
–4
; discussion 574. 5.
McMillan
DC
, Crozier
JEM
, Canna
K
, Angerson
WJ
, McArdle
CS
. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer
. Int J Colorectal Dis
. 2007
;22
(8
):881
–6
. 6.
Hacker
UT
, Hasenclever
D
, Baber
R
, Linder
N
, Busse
H
, Obermannova
R
, et al. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial
. Ann Oncol
. 2022
;33
(7
):685
–92
. 7.
Alan
O
, Telli
TA
, Basoğlu
T
, Arikan
R
, Demircan
NC
, Ercelep
O
, et al. Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment
. Clin Neurol Neurosurg
. 2020
;196
:105976
. 8.
Roncolato
FT
, Berton-Rigaud
D
, O’Connell
R
, Lanceley
A
, Sehouli
J
, Buizen
L
, et al. Validation of the modified Glasgow prognostic score (mGPS) in recurrent ovarian cancer (ROC): analysis of patients enrolled in the GCIG symptom benefit study (SBS)
. Gynecol Oncol
. 2018
;148
(1
):36
–41
. 9.
Shimada
A
, Matsuda
T
, Sawada
R
, Hasegawa
H
, Yamashita
K
, Harada
H
, et al. The modified Glasgow prognostic score is a reliable predictor of oncological outcomes in patients with rectal cancer undergoing neoadjuvant chemoradiotherapy
. Sci Rep
. 2023
;13
(1
):17111
. 10.
Chen
Z
, Nonaka
H
, Onishi
H
, Nakatani
E
, Sato
Y
, Funayama
S
, et al. Modified Glasgow Prognostic Score is predictive of prognosis for non-small cell lung cancer patients treated with stereotactic body radiation therapy: a retrospective study
. J Radiat Res
. 2021
;62
(3
):457
–64
. 11.
Proctor
MJ
, Morrison
DS
, Talwar
D
, Balmer
SM
, O’Reilly
DSJ
, Foulis
AK
, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study
. Br J Cancer
. 2011
;104
(4
):726
–34
. 12.
Tan
D
, Li
J
, Lin
T
, Tan
P
, Zhang
J
, Xiong
Q
, et al. Prognostic utility of the modified Glasgow prognostic score in urothelial carcinoma: outcomes from a pooled analysis
. J Clin Med
. 2022
;11
(21
):6261
. 13.
Qi
F
, Xu
Y
, Zheng
Y
, Li
X
, Gao
Y
. Pre-treatment Glasgow prognostic score and modified Glasgow prognostic score may be potential prognostic biomarkers in urological cancers: a systematic review and meta-analysis
. Ann Transl Med
. 2019
;7
(20
):531
. 14.
Zhang
L
, Li
L
, Liu
J
, Wang
J
, Fan
Y
, Dong
B
, et al. Meta-analysis of multiple hematological biomarkers as prognostic predictors of survival in bladder cancer
. Medicine
. 2020
;99
(30
):e20920
. 15.
Page
MJ
, McKenzie
JE
, Bossuyt
PM
, Boutron
I
, Hoffmann
TC
, Mulrow
CD
, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
. BMJ
. 2021
;372
:n71
. 16.
Wells
G
, Shea
B
, O’Connell
D
, Peterson
J
, Welch
V
, Losos
M
, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses
. [Internet]. [cited 2023 Nov 18]. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp17.
Higgins
JPT
, Thompson
SG
. Quantifying heterogeneity in a meta-analysis
. Stat Med
. 2002
;21
(11
):1539
–58
. 18.
Egger
M
, Davey Smith
G
, Schneider
M
, Minder
C
. Bias in meta-analysis detected by a simple, graphical test
. BMJ
. 1997
;315
(7109
):629
–34
. 19.
Goktas Aydin
S
, Kutlu
Y
, Muglu
H
, Aydin
A
, Acikgoz
O
, Hamdard
J
, et al. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
. Cancer Chemother Pharmacol
. 2024
;93
(1
):71
–8
. 20.
Neuberger
M
, Goly
N
, Skladny
J
, Milczynski
V
, Weiß
C
, Wessels
F
, et al. Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort
. J Cancer Res Clin Oncol
. 2023
;149
(7
):3371
–81
. 21.
Saal
J
, Grünwald
V
, Bald
T
, Ritter
M
, Brossart
P
, Tomita
Y
, et al. On-treatment modified Glasgow prognostic score provides predictive information complementary to radiological staging in metastatic urothelial carcinoma on immunotherapy
. Eur Urol Oncol
. 2023
;S2588–9311
(23
):00250
–X
.22.
Caglayan
A
, Horsanali
MO
. Can peripheral blood systemic immune response parameters predict oncological outcomes in patients with non-muscle-invasive bladder cancer
. Niger J Clin Pract
. 2023
;26
(5
):591
–8
. 23.
Noda
Y
, Naiki
T
, Sugiyama
Y
, Nagai
T
, Naiki-Ito
A
, Kawai
T
, et al. Survival outcome after reduced-port laparoscopic radical cystectomy for bladder cancer: long-term follow-up analysis
. Oncology
. 2022
;100
(8
):429
–38
. 24.
Schuettfort
VM
, Gust
K
, D’Andrea
D
, Quhal
F
, Mostafaei
H
, Laukhtina
E
, et al. Impact of the preoperative modified Glasgow Prognostic Score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder
. Minerva Urol Nephrol
. 2022
;74
(3
):302
–12
. 25.
Ferro
M
, De Cobelli
O
, Buonerba
C
, Di Lorenzo
G
, Capece
M
, Bruzzese
D
, et al. Modified Glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical cystectomy: a multicenter experience
. Medicine
. 2015
;94
(42
):e1861
. 26.
Neuberger
M
, Skladny
J
, Goly
N
, Wessels
F
, WEIß
C
, Egen
L
, et al. Baseline modified Glasgow prognostic score (mGPS) predicts radiologic response and overall survival in metastatic hormone-sensitive prostate cancer treated with docetaxel chemotherapy
. Anticancer Res
. 2022
;42
(4
):1911
–8
. 27.
Brown
JT
, Liu
Y
, Shabto
JM
, Martini
DJ
, Ravindranathan
D
, Hitron
EE
, et al. Baseline modified Glasgow prognostic score associated with survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors
. Oncologist
. 2021
;26
(5
):397
–405
. 28.
Chen
J
, Hao
L
, Zhang
S
, Zhang
Y
, Dong
B
, Zhang
Q
, et al. Preoperative fibrinogen-albumin ratio, potential prognostic factors for bladder cancer patients undergoing radical cystectomy: a two-center study
. Cancer Manag Res
. 2021
;13
:3181
–92
. 29.
Mari
A
, Muto
G
, Di Maida
F
, Tellini
R
, Bossa
R
, Bisegna
C
, et al. Oncological impact of inflammatory biomarkers in elderly patients treated with radical cystectomy for urothelial bladder cancer
. Arab J Urol
. 2020
;19
(1
):2
–8
. 30.
Kikuchi
K
, Nakamura
R
, Segawa
T
, Oikawa
H
, Ariga
H
. Modified Glasgow prognostic score can predict survival of muscle invasive bladder cancer patients after radiotherapy
. J Radiat Res
. 2020
;61
(4
):616
–21
. 31.
Stangl-Kremser
J
, Mari
A
, Suarez-Ibarrola
R
, D’Andrea
D
, Korn
SM
, Pones
M
, et al. Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients
. Urol Oncol
. 2020
;38
(6
):600.e9
–15
. 32.
Kimura
S
, D’ Andrea
D
, Soria
F
, Foerster
B
, Abufaraj
M
, Vartolomei
MD
, et al. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer
. Urol Oncol
. 2019
;37
(3
):179.e19
–8
. 33.
Miyake
M
, Morizawa
Y
, Hori
S
, Marugami
N
, Iida
K
, Ohnishi
K
, et al. Integrative assessment of pretreatment inflammation-nutrition-and muscle-based prognostic markers in patients with muscle-invasive bladder cancer undergoing radical cystectomy
. Oncology
. 2017
;93
(4
):259
–69
. 34.
Ferro
M
, Tătaru
OS
, Musi
G
, Lucarelli
G
, Abu Farhan
AR
, Cantiello
F
, et al. Modified Glasgow prognostic score as a predictor of recurrence in patients with high grade non-muscle invasive bladder cancer undergoing intravesical Bacillus calmette-guerin immunotherapy
. Diagnostics
. 2022
;12
(3
):586
. 35.
Qayyum
T
, McArdle
P
, Hilmy
M
, Going
J
, Orange
C
, Seywright
M
, et al. A prospective study of the role of inflammation in bladder cancer
. Curr Urol
. 2013
;6
(4
):189
–93
. 36.
Linton
A
, Pond
G
, Clarke
S
, Vardy
J
, Galsky
M
, Sonpavde
G
. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy
. Clin Genitourin Cancer
. 2013
;11
(4
):423
–30
. 37.
Hwang
EC
, Hwang
IS
, Yu
HS
, Kim
S-O
, Jung
SI
, Hwang
JE
, et al. Utility of inflammation-based prognostic scoring in patients given systemic chemotherapy first-line for advanced inoperable bladder cancer
. Jpn J Clin Oncol
. 2012
;42
(10
):955
–60
. 38.
Ando
K
, Sakamoto
S
, Saito
S
, Maimaiti
M
, Imamura
Y
, Sazuka
T
, et al. Prognostic value of high-sensitivity modified Glasgow prognostic score in castration-resistant prostate cancer patients who received docetaxel
. Cancers
. 2021
;13
(4
):773
. 39.
Singh
N
, Baby
D
, Rajguru
JP
, Patil
PB
, Thakkannavar
SS
, Pujari
VB
. Inflammation and cancer
. Ann Afr Med
. 2019
;18
(3
):121
–6
. 40.
Greten
FR
, Grivennikov
SI
. Inflammation and cancer: triggers, mechanisms, and consequences
. Immunity
. 2019
;51
(1
):27
–41
. 41.
Liu
J
, Lin
PC
, Zhou
BP
. Inflammation fuels tumor progress and metastasis
. Curr Pharm Des
. 2015
;21
(21
):3032
–40
. 42.
Kim
E-S
, Kim
SY
, Moon
A
. C-reactive protein signaling pathways in tumor progression
. Biomol Ther
. 2023
;31
(5
):473
–83
. 43.
Xiao
X
, Wang
S
, Long
G
. C-reactive protein is a significant predictor of improved survival in patients with advanced non-small cell lung cancer
. Medicine
. 2019
;98
(26
):e16238
. 44.
Grivennikov
SI
, Greten
FR
, Karin
M
. Immunity, inflammation, and cancer
. Cell
. 2010
;140
(6
):883
–99
. 45.
Karin
M
, Shalapour
S
. Regulation of antitumor immunity by inflammation-induced epigenetic alterations
. Cell Mol Immunol
. 2022
;19
(1
):59
–66
. 46.
Lorusso
G
, Rüegg
C
. The tumor microenvironment and its contribution to tumor evolution toward metastasis
. Histochem Cell Biol
. 2008
;130
(6
):1091
–103
. 47.
Landskron
G
, De la Fuente
M
, Thuwajit
P
, Thuwajit
C
, Hermoso
MA
. Chronic inflammation and cytokines in the tumor microenvironment
. J Immunol Res
. 2014
;2014
:149185
. 48.
Hibino
S
, Kawazoe
T
, Kasahara
H
, Itoh
S
, Ishimoto
T
, Sakata-Yanagimoto
M
, et al. Inflammation-Induced tumorigenesis and metastasis
. Int J Mol Sci
. 2021
;22
(11
):5421
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
